- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 23
The Center for Biosimilars® recaps the top stories for the week of September 23, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 23, 2019.
Number 5: Generium has received approval for the first biosimilar dornase alfa, which treats cystic fibrosis, in Russia.
Number 4: A newly published paper concludes that, as experience and analytical capabilities mature, there will be a reduced requirement for clinical data in biosimilar development.
Number 3: Two biosimilar bills, both with bipartisan sponsors, were unveiled last week.
Number 2: The Committee for Medicinal Products for Human Use issued a positive opinion for Celltrion’s subcutaneously administered biosimilar infliximab for the treatment of rheumatoid arthritis.
Number 1: The FDA has released a new suite of resources to educate patients about biosimilars.
Finally, last week, our e-newsletter asked whether you think that the 2020 launch of authorized generics of 2 of Novo Nordisk’s insulin products will help patients afford their medication.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
